输尿管节段切除术与根治性输尿管切除术治疗上尿路上皮癌的肿瘤和肾功能结局:系统回顾和荟萃分析。

IF 2.4 3区 医学 Q3 ONCOLOGY
Alejandro Calvillo-Ramirez, Lauren Chew, Laura Davis, Ana Paulina Casas-Huesca, Luis A Esparza-Miranda, Valeria Michelle Perez Alvarado, Jesse Sanchez Cardenas, Juan Carlos Angulo-Lozano, Hannia M Macias-Cruz, Luis Robles-Aquije, Gilberto Perez Rodriguez Garcia, Randy Vince
{"title":"输尿管节段切除术与根治性输尿管切除术治疗上尿路上皮癌的肿瘤和肾功能结局:系统回顾和荟萃分析。","authors":"Alejandro Calvillo-Ramirez, Lauren Chew, Laura Davis, Ana Paulina Casas-Huesca, Luis A Esparza-Miranda, Valeria Michelle Perez Alvarado, Jesse Sanchez Cardenas, Juan Carlos Angulo-Lozano, Hannia M Macias-Cruz, Luis Robles-Aquije, Gilberto Perez Rodriguez Garcia, Randy Vince","doi":"10.1016/j.urolonc.2025.05.011","DOIUrl":null,"url":null,"abstract":"<p><p>Radical nephroureterectomy (RNU) remains the standard of care for patients with upper tract urothelial carcinoma (UTUC). Segmental ureterectomy (SU) has gained traction, given its benefit of preserving renal function without compromising oncologic control, particularly in low-risk disease. However, concerns persist regarding its oncological safety. We aimed to evaluate the oncologic and renal function outcomes in patients who underwent SU and RNU for UTUC. In August 2024, we systematically searched PubMed, Embase, Medline, and Cochrane databases to identify studies comparing oncologic outcomes and renal function preservation in patients who underwent SU and RNU for UTUC. Primary outcomes were cancer-specific survival (CSS), estimated glomerular filtration rate (eGFR) changes, and postoperative eGFR. Secondary outcomes included overall survival (OS), recurrence-free survival (RFS), and metastasis-free survival (MFS). Twenty-nine studies totaling 33,241 patients were included. No significant difference in 5-year CSS was observed between SU and RNU (HR 1.04, [95% confidence interval 0.93. 1.15], P = .49). A statistically significant higher 1-year postoperative eGFR (MD 17, [7.33, 26.67], P = .0006) and less pronounced eGFR change (MD 0.70, [0.24, 1.16], P = .003) were observed in the SU group. Additionally, the 5-year OS, RFS, and MFS were comparable between the groups. SU yielded comparable oncological outcomes to RNU concerning 5-year CSS, OS, RFS, and MFS while providing a higher postoperative eGFR and lower eGFR change at 1-year follow-up. SU might represent a viable treatment modality for UTUC in low-risk and carefully selected high-risk patients, although high-quality prospective trials implementing standardized outcome reporting are needed to draw definitive conclusions.</p>","PeriodicalId":23408,"journal":{"name":"Urologic Oncology-seminars and Original Investigations","volume":" ","pages":""},"PeriodicalIF":2.4000,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Oncologic and renal function outcomes of segmental ureterectomy vs. radical nephroureterectomy in upper tract urothelial carcinoma: A systematic review and meta-analysis.\",\"authors\":\"Alejandro Calvillo-Ramirez, Lauren Chew, Laura Davis, Ana Paulina Casas-Huesca, Luis A Esparza-Miranda, Valeria Michelle Perez Alvarado, Jesse Sanchez Cardenas, Juan Carlos Angulo-Lozano, Hannia M Macias-Cruz, Luis Robles-Aquije, Gilberto Perez Rodriguez Garcia, Randy Vince\",\"doi\":\"10.1016/j.urolonc.2025.05.011\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Radical nephroureterectomy (RNU) remains the standard of care for patients with upper tract urothelial carcinoma (UTUC). Segmental ureterectomy (SU) has gained traction, given its benefit of preserving renal function without compromising oncologic control, particularly in low-risk disease. However, concerns persist regarding its oncological safety. We aimed to evaluate the oncologic and renal function outcomes in patients who underwent SU and RNU for UTUC. In August 2024, we systematically searched PubMed, Embase, Medline, and Cochrane databases to identify studies comparing oncologic outcomes and renal function preservation in patients who underwent SU and RNU for UTUC. Primary outcomes were cancer-specific survival (CSS), estimated glomerular filtration rate (eGFR) changes, and postoperative eGFR. Secondary outcomes included overall survival (OS), recurrence-free survival (RFS), and metastasis-free survival (MFS). Twenty-nine studies totaling 33,241 patients were included. No significant difference in 5-year CSS was observed between SU and RNU (HR 1.04, [95% confidence interval 0.93. 1.15], P = .49). A statistically significant higher 1-year postoperative eGFR (MD 17, [7.33, 26.67], P = .0006) and less pronounced eGFR change (MD 0.70, [0.24, 1.16], P = .003) were observed in the SU group. Additionally, the 5-year OS, RFS, and MFS were comparable between the groups. SU yielded comparable oncological outcomes to RNU concerning 5-year CSS, OS, RFS, and MFS while providing a higher postoperative eGFR and lower eGFR change at 1-year follow-up. SU might represent a viable treatment modality for UTUC in low-risk and carefully selected high-risk patients, although high-quality prospective trials implementing standardized outcome reporting are needed to draw definitive conclusions.</p>\",\"PeriodicalId\":23408,\"journal\":{\"name\":\"Urologic Oncology-seminars and Original Investigations\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2025-06-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Urologic Oncology-seminars and Original Investigations\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.urolonc.2025.05.011\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Urologic Oncology-seminars and Original Investigations","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.urolonc.2025.05.011","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

根治性肾输尿管切除术(RNU)仍然是上路尿路上皮癌(UTUC)患者的标准治疗方法。部分输尿管切除术(SU)因其在不影响肿瘤控制的情况下保留肾功能的好处而获得了广泛的关注,特别是在低风险疾病中。然而,对其肿瘤安全性的担忧仍然存在。我们的目的是评估接受SU和RNU治疗UTUC患者的肿瘤和肾功能结局。在2024年8月,我们系统地检索了PubMed, Embase, Medline和Cochrane数据库,以确定比较UTUC患者接受SU和RNU的肿瘤结局和肾功能保存的研究。主要结局是癌症特异性生存(CSS)、估计肾小球滤过率(eGFR)变化和术后eGFR。次要结局包括总生存期(OS)、无复发生存期(RFS)和无转移生存期(MFS)。29项研究共纳入33,241例患者。SU和RNU的5年CSS无显著差异(HR 1.04, 95%可信区间0.93)。1.15], p = .49)。SU组术后1年eGFR增高(MD 17, [7.33, 26.67], P = 0.0006),差异有统计学意义(MD 0.70, [0.24, 1.16], P = 0.003)。此外,两组间的5年OS、RFS和MFS具有可比性。在5年的CSS、OS、RFS和MFS方面,SU的肿瘤预后与RNU相当,同时在1年随访中提供更高的术后eGFR和更低的eGFR变化。在低风险和精心挑选的高风险患者中,SU可能是UTUC的一种可行的治疗方式,尽管需要实施标准化结果报告的高质量前瞻性试验来得出明确的结论。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Oncologic and renal function outcomes of segmental ureterectomy vs. radical nephroureterectomy in upper tract urothelial carcinoma: A systematic review and meta-analysis.

Radical nephroureterectomy (RNU) remains the standard of care for patients with upper tract urothelial carcinoma (UTUC). Segmental ureterectomy (SU) has gained traction, given its benefit of preserving renal function without compromising oncologic control, particularly in low-risk disease. However, concerns persist regarding its oncological safety. We aimed to evaluate the oncologic and renal function outcomes in patients who underwent SU and RNU for UTUC. In August 2024, we systematically searched PubMed, Embase, Medline, and Cochrane databases to identify studies comparing oncologic outcomes and renal function preservation in patients who underwent SU and RNU for UTUC. Primary outcomes were cancer-specific survival (CSS), estimated glomerular filtration rate (eGFR) changes, and postoperative eGFR. Secondary outcomes included overall survival (OS), recurrence-free survival (RFS), and metastasis-free survival (MFS). Twenty-nine studies totaling 33,241 patients were included. No significant difference in 5-year CSS was observed between SU and RNU (HR 1.04, [95% confidence interval 0.93. 1.15], P = .49). A statistically significant higher 1-year postoperative eGFR (MD 17, [7.33, 26.67], P = .0006) and less pronounced eGFR change (MD 0.70, [0.24, 1.16], P = .003) were observed in the SU group. Additionally, the 5-year OS, RFS, and MFS were comparable between the groups. SU yielded comparable oncological outcomes to RNU concerning 5-year CSS, OS, RFS, and MFS while providing a higher postoperative eGFR and lower eGFR change at 1-year follow-up. SU might represent a viable treatment modality for UTUC in low-risk and carefully selected high-risk patients, although high-quality prospective trials implementing standardized outcome reporting are needed to draw definitive conclusions.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
4.80
自引率
3.70%
发文量
297
审稿时长
7.6 weeks
期刊介绍: Urologic Oncology: Seminars and Original Investigations is the official journal of the Society of Urologic Oncology. The journal publishes practical, timely, and relevant clinical and basic science research articles which address any aspect of urologic oncology. Each issue comprises original research, news and topics, survey articles providing short commentaries on other important articles in the urologic oncology literature, and reviews including an in-depth Seminar examining a specific clinical dilemma. The journal periodically publishes supplement issues devoted to areas of current interest to the urologic oncology community. Articles published are of interest to researchers and the clinicians involved in the practice of urologic oncology including urologists, oncologists, and radiologists.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信